AstraZeneca
accelerating presence in obesity with a novel once daily oral potential for no titration high tolerability profile novel once daily oral small molecule efficacy at low doses to significant market opportunity in obesity people living with obesity obesity is driver for chronic diseases opportunity beyond obesity to address disease phase planned strong track record in renal metabolic diseases opportunity for and combinations to address broad range of morbid diseases excuse | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
26 of 45
Related slides by other companies
Equillium
Investor Presentation
August 2023
opportunity celiac disease has no approved therapies celiac disease billion dollar annual market opportunity me | Equillium
Equillium
Investor Presentation
February 2024
no approved therapies for celiac disease celiac disease billion dollar annual market opportunity me | Equillium
Kymera
Investor Presentation
December 2023
emerging clinical data support therapeutic hypothesis for degrader | Kymera
BenevolentAI
Results
March 2024
ben ulcerative colitis | BenevolentAI
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
July 2023
Investor Event
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io